Pretax income is the income that a company earns before paying income taxes. Inhibikase Therapeutics's pretax income for the
three
months ended in Dec. 2024 was $-12.13 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-27.52 Mil.
Inhibikase Therapeutics's pretax margin was %.
Inhibikase Therapeutics Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Inhibikase Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Inhibikase Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics (NAS:IKT) Pre-Tax Income Explanation
Inhibikase Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Inhibikase Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IKT has been successfully added to your 